In this free webinar, gain insight into how patient identification approaches can improve study efficiency in precision neurology programs. Attendees will learn how biomarker strategies and digital insights can support better decision-making from early development through post-launch. The featured speakers will share how real-world evidence can strengthen understanding of disease progression and patient outcomes. The speakers will also discuss how integrated evidence strategies can help optimize trial design, reduce development risk and support commercialization planning.
TORONTO, June 24, 2026 /PRNewswire/ — As precision medicine reshapes neurology drug development, sponsors are seeking smarter ways to identify the right patients, integrate biomarkers and generate meaningful evidence across the development lifecycle. Neurology programs often face added complexity because disease progression, patient heterogeneity and endpoint selection can make study design and development decisions more difficult.
This webinar explores how precision neurology strategies can help address these challenges by connecting patient identification approaches, biomarker strategies and real-world evidence across early development, clinical trials and post-launch planning. Attendees will learn how integrated evidence strategies can improve study efficiency, support more informed decision-making and help reduce development risk.
The featured speakers will discuss how biomarkers, digital insights and real-world evidence can work together to deepen understanding of disease progression, refine trial design and support commercialization planning. The session will also examine how these approaches can help sponsors identify appropriate patient populations, evaluate meaningful outcomes and generate evidence that supports development and market access goals.
Register for this webinar to learn how precision neurology can help accelerate neurology drug development through biomarkers, patient identification and real-world insight.
Join experts from PPD Clinical Research Services, Thermo Fisher Scientific, (Rachel) Zhe Rachel Angerer, Senior Director, Patient First Digital Solutions; (TJ) Tracy Jerome Stalvey, MPH, MBA, VP, Therapeutic Lead – Epilepsy, Sleep & Neuroinflammatory Disorders; Ariel Berger, MPH, Executive Director, Integrated Solutions, Real World Evidence; and David Scott, PhD, Vice President, Medical and Scientific Affairs, Neuroscience, Clario, part of Thermo Fisher Scientific, for the live webinar on Wednesday, July 15, 2026, at 10am EDT (4pm CEST/EU-Central).
For more information, or to register for this event, visit Precision Neurology Made Practical: Faster Development Through Biomarkers and Real-World Insight.
ABOUT XTALKS
Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.
Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what’s next.
To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/precision-neurology-made-practical-faster-development-through-biomarkers-and-real-world-insight-upcoming-webinar-hosted-by-xtalks-302808371.html
SOURCE Xtalks
